TSTickerStarGet alerts

CalciMedica Reports Q3 2026 Financial Results; Net Loss Narrows to $1.7M on $3.1M Other Income

CalciMedica reported a Q3 2026 net loss of $1.7 million, or $0.24 per basic and diluted share, compared to a net loss of $7.8 million, or $2.59 per share, in Q3 2025, as a $3.3 million gain from changes in the fair value of financial instruments offset operating expenses. Operating expenses decreased to $4.8 million from $5.6 million year-over-year, with R&D spending declining to $2.3 million from $3.9 million. Cash, cash equivalents and short-term investments were $13.8 million as of September 30, 2026, expecte...

Share this story

Key takeaways

  • Net loss narrowed 78% year-over-year to $1.7 million in Q3 2026 from $7.8 million in Q3 2025, driven by a $3.3 million non-cash gain on financial instruments.

  • EPS improved to negative $0.24 per share from negative $2.59 per share, reflecting both the reduced net loss and the impact of a 1-for-5 reverse stock split.

  • R&D expenses declined 40% year-over-year to $2.3 million due to decreased nonclinical and clinical trial activities.

  • G&A expenses increased 38% year-over-year to $2.4 million, partially offsetting R&D savings.

  • Cash position of $13.8 million provides runway into the second half of 2027.

  • Auxora Phase 1b proof-of-concept data in pulmonary hypertension and CM5480 IND submission both anticipated in mid-2027.

Key metrics

Net lossQ3 2026 (three months ended September 30, 2026)
$1.7 million78% improvement from $7.8 million net loss
Net loss per share - basic and dilutedQ3 2026
$0.24Improved from $2.59 per share
Net loss (YTD)Nine months ended September 30, 2026
$4.4 million77% improvement from $18.8 million net loss
Net loss per share - basic and diluted (YTD)Nine months ended September 30, 2026
$0.96Improved from $6.61 per share
Research and development expensesQ3 2026
$2.3 millionDecreased 40% from $3.9 million
General and administrative expensesQ3 2026
$2.4 millionIncreased 38% from $1.8 million
Cash, cash equivalents and short-term investmentsAs of September 30, 2026
$13.8 million
Change in fair value of financial instrumentsQ3 2026
$3.3 millionShift from negative $2.0 million to positive $3.3 million

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow CALC in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert